Investor Relations

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

CR-000172

SEC Filings

SEC Filings

Filing date Form Description Filing Group Downloads
8-K

Report of unscheduled material events or corporate event

Current Reports
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
10-Q

Quarterly report which provides a continuing view of a company's financial position

Quarterly Filings
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
3

Initial filing by director officer or owner of more than ten percent.

3,4,5
3

Initial filing by director officer or owner of more than ten percent.

3,4,5
8-K

Report of unscheduled material events or corporate event

Current Reports
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5

Data provided by Kaleidoscope.

Featured Report

2019 Annual Report (PDF)